{"preliminary_commentary":{"by_channel":{"x_thread":120,"podcast":31,"youtube":21},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03519971\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PACIFIC2","nct_id":"NCT03519971","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pacific2-nct03519971. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Durvalumab ((MEDI4736) in concurrence with platinum-based chemo-radiation therapy.\n\nAll patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:\n\n* cisplatin/etoposide\n* carboplatin/paclitaxel\n* pemetrexed/cisplatin\n* pemetrexed/carboplatin\n\nAt the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive durvalumab as consolidation treatment.","label":"Arm 1: Durvalumab + platinum-based chemotherapy and radiation","type":"EXPERIMENTAL"},{"description":"Placebo in concurrence with platinum-based chemo-radiation therapy.\n\nAll patients will receive 1 of the following platinum-based standard of care chemotherapy options, based on Investigator discretion, in addition to radiation therapy:\n\n* cisplatin/etoposide\n* carboplatin/paclitaxel\n* pemetrexed/cisplatin\n* pemetrexed/carboplatin\n\nAt the completion of standard of care chemoradiation therapy (SoC CRT), patients with complete response, partial response or stable disease will continue to receive placebo as consolidation treatment.","label":"Arm 2: Placebo + platinum-based chemotherapy and radiation","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-03-09","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":328,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"},{"name":"Cisplatin/ Etoposide","otherNames":[],"type":"DRUG"},{"name":"Carboplatin/ Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed/ Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed/ Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Radiation","otherNames":[],"type":"RADIATION"}],"last_update":"2026-07-14","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-09-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days)."}],"references":[],"start_date":{"date":"2018-03-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03519971"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pacific2-nct03519971"}